Literature DB >> 17654681

No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique.

Eli Konen1, Husam Ghoti, Orly Goitein, Asher Winder, Tammi Kushnir, Yael Eshet, Eliezer Rachmilewitz.   

Abstract

The method of cardiovascular T2 magnetic resonance imaging (MRI) allows in vivo estimation of iron in the heart and liver and was used to measure the degree of iron overload in 10 transfused MDS patients (average 90 blood units) and in 3 patients with congenital hemolytic anemia. In all MDS patients iron overload was found in the liver but not in the heart. Patients with congenital anemias had iron in both organs despite iron chelation. It is possible that in MDS more time and more transfusions are required to induce iron accumulation in the myocardium. Therefore, cardiac MRI may serve as a diagnostic tool to assess if and when iron chelation is indicated. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17654681     DOI: 10.1002/ajh.20980

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  16 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

3.  Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Franklin Hendrick; Erika Friedmann; Maria R Baer; Steven D Gore; Medha Sasane; Carole Paley; Amy J Davidoff
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

Review 4.  Liver iron content determination by magnetic resonance imaging.

Authors:  Konstantinos Tziomalos; Vassilios Perifanis
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

Review 5.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

6.  Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patients: insights from an Italian network.

Authors:  Alessia Pepe; Michele Rizzo; Sara Galimberti; Claudia Baratè; Esther Natalie Oliva; Francesco Arcioni; Sergio Storti; Stefania Renne; Massimo Midiri; Gennaro Restaino; Vincenzo Positano; Maurizio Mangione; Antonella Meloni
Journal:  Ann Hematol       Date:  2021-03-19       Impact factor: 3.673

Review 7.  The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

Review 8.  Cardiac iron across different transfusion-dependent diseases.

Authors:  John C Wood
Journal:  Blood Rev       Date:  2008-12       Impact factor: 8.250

9.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

Review 10.  Deferasirox : a review of its use in the management of transfusional chronic iron overload.

Authors:  Lily P H Yang; Susan J Keam; Gillian M Keating
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.